Date: November 1, 2022
Time: 9:00am (PDT), 12:00pm (EDT), 5:00pm (CET)
Rapid and efficient organism identification and antimicrobial susceptibility reports are paramount for patient survival during sepsis. The Bruker MBT Sepsityper® Kit US IVD allows harvesting of microorganism directly from positive blood cultures and pairs it with the Bruker MALDI Biotyper® CA System for rapid identification of bacterial isolates using MALDI-TOF technology. Here we compare the accuracy of the MBT Sepsityper® Kit US IVD for bacterial identification to culture-based methods. Further, as an off-label use of the kit, we compare the antimicrobial susceptibility results for Gram-negative bacteria setup directly using the harvested pellet to the established method in the laboratory. To conclude the webinar, there will be an interactive Q & A session.
- List three different methods/technologies used to rapidly identify microorganisms directly from positive blood cultures.
- Summarize the percent agreement of identifications between MBT Sepsityper® and standard culture.
- Define categorical agreement as stated by CLSI and list the three error categories.
- Recall the time savings to the final blood culture report when microorganism identification and AST are acquired using the MBT Sepsityper® and how this can impact the survival rate for a patient with a BSI.
Any data generated outside the cleared intended use cannot be used for clinical diagnostic purposes.
Webinars will be available for unlimited on-demand viewing after live event.